査読の際の注意点、チェックポイント: 原著論文

2018/07/28 更新

  1. Title and authors
  2. Abstract
  3. Introduction
  4. Materials and Methods
    • Database and software versions
    • Immunohistochemistry
    • Real-time PCR
    • Regression analysis
    • 腸内細菌を扱った論文
  5. Results: including experimental design
  6. Discussion
  7. Reference
  8. Table
  9. Figure


Title and authors




Is Abstract a summary of the whole paper?

Abstract に論文の内容が過不足なく要約されているかどうか。

In a poorly prepared manuscript, important information is sometimes missing in Abstract. The structure of my ideal Abstract is as follows (2). See Abstract の書き方.

  1. General introduction. 1 - 2 sentences.
  2. Specific introduction, or detailed background. 1 - 2 sentences.
  3. One sentence clearly stating the general problem being assessed by this paper.
  4. One sentence summarising the main results of this paper. Started with a phrase like Here we show...
  5. Result 1, result 2, result 3,... If experiments are organized very well, not many explanatory sentences should be needed.
  6. One or two sentences to put the results into a general context. Should be closely related to the aforementioned problem.
  7. Two to three sentences to provide a broader perspective.

I think that the last sentence of Abstract should NOT be a simple description about one of experiments, although some papers actually do.


Introduction is not a review

Do not describe unnecessary details, which are not related to the contents of the paper, like a review.

Materials and Methods

In this section, authors are requested to provide enough information with which an experienced group in the same research field can reproduce the results. It was a terrible shame that a Japanese group published a protocol to produce STAP cells (3; retracted), which was reported as a different paper (also retracted). They should have provided the information in the original paper. I do not understand why coauthors are still comfortably working in the same institute after retracting both papers.



Database and software versions


Many biological databases, as well as analyzing softwares, are frequently updated recently. Using different version of database and software results in different results. It is necessary to describe the version in M&M section to ensure reproducibility (4).


  • The authors have used MEGA 7.0 for the phylogenetic analysis. Currently, MEGA 10.0 with advanced functions is available. I would recommend to revise the phylogenetic analysis using the latest version.


Author guideline package of some journals provide useful information about immunohistochemistry (4).

  • Provide the origin (e.g. human, rat, zebrafigh) and sequence of immunogen for antibody.
  • If commercial antibodies were used, provide the name of company, immunized species, and monoclonal/polyclonal.
  • Characterization information such as western blot, radioimmunoassay and ELISA should be included. This is because it is difficult to find non-specific bindings in immunohistochemistry.
  • Negative controls: pre-adsorption with the original antigen, and/or incubation with secondary antibody only.
  • If transfected cells are used, two negative controls are required. Non-transfected cells stained with primary and secondary antibodies, and transfected cells stained with secondary antibody only.

Real-time PCR

To be updated. See minimum information for the publication of real-time quantitative PCR experiments guidelines for now.

Regression analysis

If the paper performs regression analyses, check the following points.

  • Is the selection of function (linear, exponential, logarithmic etc) appropriate? Computers can calculate how their data fit to the specific function, but authors determine functions to calculate.
  • Are the coefficient of determination and statistic results shown?




Results: including experimental design

Time- and concentration-dependency?

1 点のみのデータは常に危険を伴うことを覚えておこう。薬剤やストレスなど、何らかの処理を生物に与える場合には、以下の点に注意する必要がある。

  • Dose と time を振る。
  • タイムコースの場合、control は Time 0 だけではなく、全ての time points についてとるべき。
  • Solvent を使っている場合、control は未処理のものと solvent control の両方をとるべき。

If the paper examines the effect of some reagents on animals or cells, the experiment should test dose- and time-dependency in general.

A good example is the this Figure (1). If you have only one timepoint, for example 1 h, you would conclude that "Bcl-2 protein expression was significantly increased."

However, if you have only the 12 h result, you should conclude in the other way; "Bcl-2 was decreased". Analyzing limited timepoints generally have a risk to miss important results.

Cui et al. 2012a

Bar graph

  • Scale, X and Y labels are OK?
  • Error bar, SD or SE? N is mentioned in legend?
  • If the value is normalized, the data should be carefully checked.


Pointing out statistical mistakes is often difficult because reviewers should know well about statistics. I hope that this page helps Japanese people to learn statistics.

  • Duncan's multiple-range test is now widely criticized because of its poor control over type I error. The *** test is a better option.


Figure legend

Figure legend is getting longer and longer nowadays. Many papers mention results in figure legends. Alothough there are many styles, in my opinion, the optimum length of legend is the minimum to provide enough information for understanding the Figure by themselves.

You might want to point out this if the paper does not include the following information:

  • Number of samples (N)
  • Meaning of error bars. Standard error or standard deviation.
  • Meaning of asterisks. Typically P < 0.05.
  • Abbreviations used in Figures



一言コメントをどうぞ! (100 字まで)



  1. Cui et al. 2012a. Propofol prevents autophagic cell death following oxygen and glucose deprivation in PC12 cells and cerebral ischemia-reperfusion injury in rats. PLoS ONE 7, e35324.
  2. How to construct a Nature summary paragraph. Link.
  3. Obokata et al. 2014. Essential technical tips for STAP cell conversion culture from somatic cells. Protocol Exchange. doi:10.1038/protex.2014.008
  4. Author information pack. General and Comparative Endocrinology.